Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Knowns and Known Unknowns of Gastrointestinal Stromal Tumor Adjuvant Therapy.

Gastroenterology clinics of North America - 1 Sept 2016

Martínez-Marín Virginia, Maki Robert G

Abstract excerpt

The first 15 years of management of gastrointestinal stromal tumor (GIST) have led to 3 lines of therapy for metastatic disease: imatinib, sunitinib, and regorafenib. In the adjuvant setting, imatinib is usually given for 3 years postoperatively to patients with higher-risk primary tumors that are completely resected. In this review, issues regarding GIST adjuvant therapy are discussed. It is hoped this review...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemotherapy, Adjuvant
Share to Gastrointestinal Neoplasms
Share to Gastrointestinal Stromal Tumors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoadjuvant Therapy

Share to Phenylurea Compounds

Share to Pyrroles

Share to Receptor, Platelet-Derived Growth Factor alpha

Share to Sunitinib

Source

Identifiers

PMID: 27546844
DOI: 10.1016/j.gtc.2016.04.006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Knowns and Known Unknowns of Gastrointestinal Stromal Tumor Adjuvant Therapy.PMID 27546844Read ↗

Adjuvant therapy of gastrointestinal stromal tumors (GIST).Semantic proximity Read ↗

Gastrointestinal Stromal Tumor: Current Approaches and Future Directions in the Treatment of Advanced Disease.Semantic proximity Read ↗

Gastrointestinal Stromal Tumors (GISTs): Novel Therapeutic Strategies with Immunotherapy and Small Molecules.Semantic proximity Read ↗

Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib.Semantic proximity Read ↗

An updated review of the treatment landscape for advanced gastrointestinal stromal tumors.Semantic proximity Read ↗

Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.Semantic proximity Read ↗

Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges.Semantic proximity Read ↗

Preoperative adjuvant therapy for locally advanced and recurrent/metastatic gastrointestinal stromal tumors: a retrospective studySemantic proximity Read ↗

New treatment strategies for advanced-stage gastrointestinal stromal tumours.Semantic proximity Read ↗

Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations.Semantic proximity Read ↗

Translational insights into gastrointestinal stromal tumor and current clinical advances.Semantic proximity Read ↗

Old Tyrosine Kinase Inhibitors and Newcomers in Gastrointestinal Cancer Treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.